The Technology sector is abuzz with excitement as analysts weigh in on International Business Machines (IBM), Salesforce (CRM), and Enfusion (ENFN). Let's dive into the latest opinions from the experts.

IBM has been a topic of interest, with Bernstein analyst Toni Sacconaghi maintaining a Hold rating and setting a price target of $185.00. Sacconaghi has a proven track record, with an average return of 7.0% and a 58.4% success rate. Currently, the analyst consensus on IBM is a Hold, with an average price target of $197.46.

On the other hand, Salesforce has received a more subdued review from Bernstein analyst Mark Moerdler, who maintained a Sell rating and set a price target of $236.00. Moerdler's expertise in the Technology sector is impressive, with an average return of 21.0% and a 80.3% success rate. The general consensus on Salesforce is a Moderate Buy, with a $307.90 average price target.

Enfusion, a relatively newer player in the market, has caught the attention of Morgan Stanley analyst Michael Infante. Infante maintained a Buy rating and set a price target of $11.00, citing the company's potential for growth. Infante has a solid track record, with an average return of 5.3% and a 66.7% success rate. The analyst consensus on Enfusion is a Moderate Buy, with an average price target of $9.67.

Tech Stocks in the Spotlight: Uncovering the Analysts' Opinions

Actions